Clinical Trial Update: A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GDC-0980 for recurrent or persistent endometrial cancer has been completed. The study was sponsored by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• GDC-0980

Snippet

Sponsor: Genentech, Inc. | Conditions: Endometrial Carcinoma | Phase 2 | Status: COMPLETED